Lauren L. O'MAhoney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren L. O'MAhoney has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Kamlesh Khunti
Diabetes Research Centre, College of Life Sciences University of Leicester Leicester UK
6 shared publications - Matthew D. Campbell
Department of Sport, Exercise and Rehabilitation, Faculty of Health and Life Sciences, Northumbria University, Newcastle-upon-Tyne, UK
6 shared publications Ash Routen
Leicester Diabetes Centre, University of Leicester, Leicester, UK
4 shared publications- Noppadol Kietsiriroje
Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
4 shared publications - Roz Shafran
UCL Great Ormond Street Institute of Child Health University College London London UK
4 shared publications - Amitava Banerjee
Institute of Health Informatics, University College London, London, UK
3 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Outcome measurement for multiple long-term conditions research across health-care settings – an overview of reviews
Background: Multiple long-term conditions (MLTC) represent a growing global public health challenge, yet research is hindered by inconsistent outcomes across health-care settings and populations. Although several core outcome sets (COS) have been developed, important gaps remain in their coverage, inclusivity, and measurement validity. This overview of reviews summarised outcomes reported in systematic reviews of MLTC research to identify existing domains, describe how measurement instruments were addressed, and highlight areas requiring standardisation. Methods: We conducted a prospectively registered overview of reviews (PROSPERO CRD420251005152), following PRISMA, PRIOR, and SWiM guidelines. Eligible reviews included adults or children with MLTC—defined as the coexistence of two or more chronic conditions—and reported on outcome measures or COS relevant to this population. Five databases (MEDLINE, CINAHL, Scopus, Cochrane Library, COMET (Core Outcome Measures in Effectiveness Trials)) were searched from inception to April 2025. Two reviewers independently screened, extracted data, and appraised quality using the Joanna Briggs Institute checklist. A narrative synthesis mapped outcomes by domain (clinical, patient-reported, service/system, engagement/experience), care setting, and population subgroup. Results: From 6331 records, 10 reviews met inclusion criteria, encompassing 709 primary studies. Four developed COS, and six mapped outcomes without proposing COS. Quality of life and health-care utilisation were most consistently reported; treatment burden, patient engagement, and child outcomes were infrequently assessed. Existing COS advanced standardisation but remained limited in stakeholder diversity, geographic scope, and specification of measurement instruments, with only one including low- and middle-income countries. Conclusions: Greater inclusivity, validation, and global applicability are needed to operationalise agreed domains and improve comparability across MLTC research.
- 19 June 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessOutcome measurement for multiple long-term conditions research across health-care settings – an overview of reviews
Background: Multiple long-term conditions (MLTC) represent a growing global public health challenge, yet research is hindered by inconsistent outcomes across health-care settings and populations. Although several core outcome sets (COS) have been developed, important gaps remain in their coverage, inclusivity, and measurement validity. This overview of reviews summarised outcomes reported in systematic reviews of MLTC research to identify existing domains, describe how measurement instruments were addressed, and highlight areas requiring standardisation. Methods: We conducted a prospectively registered overview of reviews (PROSPERO CRD420251005152), following PRISMA, PRIOR, and SWiM guidelines. Eligible reviews included adults or children with MLTC—defined as the coexistence of two or more chronic conditions—and reported on outcome measures or COS relevant to this population. Five databases (MEDLINE, CINAHL, Scopus, Cochrane Library, COMET (Core Outcome Measures in Effectiveness Trials)) were searched from inception to April 2025. Two reviewers independently screened, extracted data, and appraised quality using the Joanna Briggs Institute checklist. A narrative synthesis mapped outcomes by domain (clinical, patient-reported, service/system, engagement/experience), care setting, and population subgroup. Results: From 6331 records, 10 reviews met inclusion criteria, encompassing 709 primary studies. Four developed COS, and six mapped outcomes without proposing COS. Quality of life and health-care utilisation were most consistently reported; treatment burden, patient engagement, and child outcomes were infrequently assessed. Existing COS advanced standardisation but remained limited in stakeholder diversity, geographic scope, and specification of measurement instruments, with only one including low- and middle-income countries. Conclusions: Greater inclusivity, validation, and global applicability are needed to operationalise agreed domains and improve comparability across MLTC research.
- Open Access
- 20 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5416-5420
Clarity in Reporting Multiple Long‐Term Conditions in Research: The Need for Consistency and Consensus
Multiple long‐term conditions (MLTC), also known as multimorbidity, affects a substantial proportion of the global population and represents an increasing challenge to healthcare systems, individuals and society. Despite increasing attention and investment, progress in MLTC research is hindered by conceptual inconsistencies and a lack of standardised reporting. Challenges include varied terminology, differing definitions of chronicity and substantial variation in the number and type of conditions included across studies. These inconsistencies contribute to differences in prevalence estimates and reduced comparability across the literature. Moreover, many clinical trials involve participants living with MLTC but do not collect or report co‐existing conditions, leaving their experiences largely invisible within research and limiting applicability of findings for this population. Heterogeneity in disease clusters and outcome selection further complicates evidence synthesis. In this commentary, we highlight that improving the clarity and impact of MLTC research requires transparent reporting of MLTC status, the use of consensus‐based condition lists, identification of clinically and socially meaningful clusters and prioritisation of outcomes aligned with what matters most to people living with MLTC (e.g., independence, treatment burden and quality of life). Improving reporting practices is needed to generate evidence that improves care, informs policy and enhances the wellbeing of people living with MLTC.
- 20 April 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 5416-5420
Open AccessClarity in Reporting Multiple Long‐Term Conditions in Research: The Need for Consistency and Consensus
Multiple long‐term conditions (MLTC), also known as multimorbidity, affects a substantial proportion of the global population and represents an increasing challenge to healthcare systems, individuals and society. Despite increasing attention and investment, progress in MLTC research is hindered by conceptual inconsistencies and a lack of standardised reporting. Challenges include varied terminology, differing definitions of chronicity and substantial variation in the number and type of conditions included across studies. These inconsistencies contribute to differences in prevalence estimates and reduced comparability across the literature. Moreover, many clinical trials involve participants living with MLTC but do not collect or report co‐existing conditions, leaving their experiences largely invisible within research and limiting applicability of findings for this population. Heterogeneity in disease clusters and outcome selection further complicates evidence synthesis. In this commentary, we highlight that improving the clarity and impact of MLTC research requires transparent reporting of MLTC status, the use of consensus‐based condition lists, identification of clinically and socially meaningful clusters and prioritisation of outcomes aligned with what matters most to people living with MLTC (e.g., independence, treatment burden and quality of life). Improving reporting practices is needed to generate evidence that improves care, informs policy and enhances the wellbeing of people living with MLTC.
- Open Access
- 13 January 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70210
Hybrid closed‐loop insulin delivery improves glycaemic control compared with sensor‐augmented pump therapy: A meta‐analysis of ‘free‐living’ randomised trials in type 1 diabetes
Aim: Although hybrid closed‐loop systems (HCLS) and sensor‐augmented pump (SAP) therapy are advanced diabetes management technologies for type 1 diabetes, their relative efficacy in optimising glycaemic control is not fully established. This meta‐analysis evaluated the impact of HCLS versus SAP therapy on glucose regulation across multiple randomised controlled trials (RCTs) and randomised crossover trials (RCOs). The primary aim was to determine the efficacy of HCLS in improving glycaemic control, reducing glucose variability and enhancing time in range (TIR) compared with SAP therapy. Methods: The review was prospectively registered with the International Prospective Register of Systematic Reviews as CRD42023488722. Data from 27 studies involving over 1000 participants were analysed. The studies included both RCTs and RCOs that compared HCLS with SAP therapy. Key metrics assessed were mean glucose levels, glucose variability (coefficient of variation and standard deviation), low blood glucose index (LBGI), high blood glucose index (HBGI), glycated haemoglobin (HbA1c) and TIR (3.9–10.0 mmol/L). Hyperglycaemia and hypoglycaemia outcomes were also evaluated. Results: HCLS significantly reduced mean glucose levels by 2.0 mg/dL compared with SAP therapy. It also decreased glucose variability, including CV and SD, and reduced LBGI, HBGI and HbA1c. HCLS increased TIR by 8.8%. Regarding hyperglycaemia, HCLS reduced the time spent above 10 mmol/L by 7.8%, above 13.9 mmol/L by 3.63% and above 16.7 mmol/L by 0.88%. Hypoglycaemia outcomes showed modest improvements, with reductions in time below 3 mmol/L by 0.10% and below 3.9 mmol/L by 0.72%. Conclusions: Our findings support HCLS as a superior modality to SAP therapy in improving glycaemic control, particularly in paediatric populations. HCLS effectively reduces hyperglycaemia and increases TIR, with modest effects on hypoglycaemia. The clinical implications are significant, highlighting the advantages of HCLS in optimising glucose regulation and mitigating glycaemic variability. This technology offers improved glycaemic control and enhanced quality of life for people living with type 1 diabetes.
- 13 January 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70210
Open AccessHybrid closed‐loop insulin delivery improves glycaemic control compared with sensor‐augmented pump therapy: A meta‐analysis of ‘free‐living’ randomised trials in type 1 diabetes
Aim: Although hybrid closed‐loop systems (HCLS) and sensor‐augmented pump (SAP) therapy are advanced diabetes management technologies for type 1 diabetes, their relative efficacy in optimising glycaemic control is not fully established. This meta‐analysis evaluated the impact of HCLS versus SAP therapy on glucose regulation across multiple randomised controlled trials (RCTs) and randomised crossover trials (RCOs). The primary aim was to determine the efficacy of HCLS in improving glycaemic control, reducing glucose variability and enhancing time in range (TIR) compared with SAP therapy. Methods: The review was prospectively registered with the International Prospective Register of Systematic Reviews as CRD42023488722. Data from 27 studies involving over 1000 participants were analysed. The studies included both RCTs and RCOs that compared HCLS with SAP therapy. Key metrics assessed were mean glucose levels, glucose variability (coefficient of variation and standard deviation), low blood glucose index (LBGI), high blood glucose index (HBGI), glycated haemoglobin (HbA1c) and TIR (3.9–10.0 mmol/L). Hyperglycaemia and hypoglycaemia outcomes were also evaluated. Results: HCLS significantly reduced mean glucose levels by 2.0 mg/dL compared with SAP therapy. It also decreased glucose variability, including CV and SD, and reduced LBGI, HBGI and HbA1c. HCLS increased TIR by 8.8%. Regarding hyperglycaemia, HCLS reduced the time spent above 10 mmol/L by 7.8%, above 13.9 mmol/L by 3.63% and above 16.7 mmol/L by 0.88%. Hypoglycaemia outcomes showed modest improvements, with reductions in time below 3 mmol/L by 0.10% and below 3.9 mmol/L by 0.72%. Conclusions: Our findings support HCLS as a superior modality to SAP therapy in improving glycaemic control, particularly in paediatric populations. HCLS effectively reduces hyperglycaemia and increases TIR, with modest effects on hypoglycaemia. The clinical implications are significant, highlighting the advantages of HCLS in optimising glucose regulation and mitigating glycaemic variability. This technology offers improved glycaemic control and enhanced quality of life for people living with type 1 diabetes.
- Top Cited PapersOpen Access
- 7 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
The risk of Long Covid symptoms: a systematic review and meta-analysis of controlled studies
The global evidence on the risk of symptoms of Long Covid in general populations infected with SARS-CoV-2 compared to uninfected comparator/control populations remains unknown. We conducted a systematic literature search using multiple electronic databases from January 1, 2022, to August 1, 2024. Included studies had ≥100 people with confirmed or self-reported COVID-19 at ≥28 days following infection onset, and an uninfected comparator/control group. Results were summarised descriptively and meta-analyses were conducted to derive pooled risk ratio estimates. 50 studies totaling 14,661,595 people were included. In all populations combined, there was an increased risk of a wide range of 39 out of 40 symptoms in those infected with SARS‑CoV‑2 compared to uninfected controls. The symptoms with the highest pooled relative risks were loss of smell (RR 4.31; 95% CI 2.66, 6.99), loss of taste (RR 3.71; 95% CI 2.22, 7.26), poor concentration (RR 2.68; 95% CI 1.66, 4.33), impaired memory (RR 2.53; 95% CI 1.82, 3.52), and hair loss/alopecia (RR 2.38; 95% CI 1.69, 3.33). This evidence synthesis, of 50 controlled studies with a cumulative participant count exceeding 14 million people, highlights a significant risk of diverse long-term symptoms in individuals infected with SARS-CoV-2, especially among those who were hospitalised.
- 7 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
Top Cited PapersOpen AccessThe risk of Long Covid symptoms: a systematic review and meta-analysis of controlled studies
The global evidence on the risk of symptoms of Long Covid in general populations infected with SARS-CoV-2 compared to uninfected comparator/control populations remains unknown. We conducted a systematic literature search using multiple electronic databases from January 1, 2022, to August 1, 2024. Included studies had ≥100 people with confirmed or self-reported COVID-19 at ≥28 days following infection onset, and an uninfected comparator/control group. Results were summarised descriptively and meta-analyses were conducted to derive pooled risk ratio estimates. 50 studies totaling 14,661,595 people were included. In all populations combined, there was an increased risk of a wide range of 39 out of 40 symptoms in those infected with SARS‑CoV‑2 compared to uninfected controls. The symptoms with the highest pooled relative risks were loss of smell (RR 4.31; 95% CI 2.66, 6.99), loss of taste (RR 3.71; 95% CI 2.22, 7.26), poor concentration (RR 2.68; 95% CI 1.66, 4.33), impaired memory (RR 2.53; 95% CI 1.82, 3.52), and hair loss/alopecia (RR 2.38; 95% CI 1.69, 3.33). This evidence synthesis, of 50 controlled studies with a cumulative participant count exceeding 14 million people, highlights a significant risk of diverse long-term symptoms in individuals infected with SARS-CoV-2, especially among those who were hospitalised.
- Open Access
- 21 December 2023
- Published by Wiley in Health Expectations
- Vol. 27 (1) , e13944
Health and social care experience and research perception of different ethnic minority populations in the East Midlands, United Kingdom (REPRESENT study)
Introduction: Ethnic minority populations experience significant health and social care disparities; despite experiencing a greater burden of diseases, these groups are underrepresented in health and social care research. Consequently, related research can be less applicable to these population groups. The REPRESENT study aims to explore the health and social care experiences of ethnic minorities and other minoritised populations, their research interests and appropriate research practices.Methods: Focus groups and semistructured interviews were conducted between May and September 2022 with members of a number of ethnic minority communities in England. Data were audio recorded, transcribed and thematically coded using NVivo 12. Rigour was determined through extensive sampling, iterative data collection and analysis.Findings: Fifty‐two ethnic minority members were engaged in group interviews and one‐to‐one interviews. Participants included representatives of the following groups: African Caribbean, Eastern European, Gypsy Travellers, Lesbian, Gay, Bisexual, Transgender, Queer, Intersex and Asexual+, Refugee/Asylum Seekers, Somali and South Asian communities. Interviews were also conducted with ethnic minority healthcare providers and researchers. Three overarching categories were identified: health information, medical service experiences, health and social care concerns and health research. Health and social care services challenges were mostly attributed to discrimination, delayed services, poor cultural relevance and language and cultural barriers. The most influential information sources were local community organisations and word‐of‐mouth. The main health and social care concerns were chronic long‐term health conditions, mental health, maternal health and child development. Recommendations for research involved understanding the motivations for participation, improving communication and empowering communities. Top research priorities were long‐term health conditions, health promotion and education, early care interventions and understanding community needs.Interpretation: Discrimination and bias in health and social care provision have severe implications for worsening ethnic health inequalities. Healthcare commissioning authorities and policymakers can leverage the preference of ethnic minority groups for pharmacy services and community organisations to improve access to care. Improving research interest and engagement requires understanding individual community needs, community sensitivity, research relevance and cultural appropriateness.Patient or Public Contribution: Members of ethnic minority Patient and Public Involvement and Engagement group and Community Advisory Board supported the REPRESENT study design, conceptualisation and report development.
- 21 December 2023
- Published by Wiley in Health Expectations
- Vol. 27 (1) , e13944
Open AccessHealth and social care experience and research perception of different ethnic minority populations in the East Midlands, United Kingdom (REPRESENT study)
Introduction: Ethnic minority populations experience significant health and social care disparities; despite experiencing a greater burden of diseases, these groups are underrepresented in health and social care research. Consequently, related research can be less applicable to these population groups. The REPRESENT study aims to explore the health and social care experiences of ethnic minorities and other minoritised populations, their research interests and appropriate research practices.Methods: Focus groups and semistructured interviews were conducted between May and September 2022 with members of a number of ethnic minority communities in England. Data were audio recorded, transcribed and thematically coded using NVivo 12. Rigour was determined through extensive sampling, iterative data collection and analysis.Findings: Fifty‐two ethnic minority members were engaged in group interviews and one‐to‐one interviews. Participants included representatives of the following groups: African Caribbean, Eastern European, Gypsy Travellers, Lesbian, Gay, Bisexual, Transgender, Queer, Intersex and Asexual+, Refugee/Asylum Seekers, Somali and South Asian communities. Interviews were also conducted with ethnic minority healthcare providers and researchers. Three overarching categories were identified: health information, medical service experiences, health and social care concerns and health research. Health and social care services challenges were mostly attributed to discrimination, delayed services, poor cultural relevance and language and cultural barriers. The most influential information sources were local community organisations and word‐of‐mouth. The main health and social care concerns were chronic long‐term health conditions, mental health, maternal health and child development. Recommendations for research involved understanding the motivations for participation, improving communication and empowering communities. Top research priorities were long‐term health conditions, health promotion and education, early care interventions and understanding community needs.Interpretation: Discrimination and bias in health and social care provision have severe implications for worsening ethnic health inequalities. Healthcare commissioning authorities and policymakers can leverage the preference of ethnic minority groups for pharmacy services and community organisations to improve access to care. Improving research interest and engagement requires understanding individual community needs, community sensitivity, research relevance and cultural appropriateness.Patient or Public Contribution: Members of ethnic minority Patient and Public Involvement and Engagement group and Community Advisory Board supported the REPRESENT study design, conceptualisation and report development.
- Open Access
- 17 March 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (4) , 771-773
Patient and public involvement within epidemiological studies of long COVID in the UK
- 17 March 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (4) , 771-773
Open AccessPatient and public involvement within epidemiological studies of long COVID in the UK
- Open Access
- 10 December 2022
- Published by Springer Nature in European Journal of Nutrition
- Vol. 62 (3) , 1231-1238
Dietary fat intake is associated with insulin resistance and an adverse vascular profile in patients with T1D: a pooled analysis
Background: Insulin resistance (IR) increases vascular risk in individuals with Type 1 Diabetes (T1D). We aimed to investigate the relationship between dietary intake and IR, as well as vascular biomarkers in T1D. Methods: Baseline data from three randomised controlled trials were pooled. Estimated glucose disposal rate (eGDR) was used as an IR marker. Employing multivariate nutrient density substitution models, we examined the association between macronutrient composition and IR/vascular biomarkers (tumour necrosis factor-α, fibrinogen, tissue factor activity, and plasminogen activator inhibitor-1). Results: Of the 107 patients, 50.5% were male with mean age of 29 ± 6 years. Those with lower eGDR were older with a longer diabetes duration, higher insulin requirements, and an adverse vascular profile (p < 0.05). Patients with higher degrees of IR had higher total energy intake (3192 ± 566 vs. 2772 ± 268 vs. 2626 ± 395 kcal/d for eGDR < 5.1 vs. 5.1–8.6 vs. ≥ 8.7 mg/kg/min, p < 0.001) and consumed a higher absolute and proportional amount of fat (47.6 ± 18.6 vs. 30.4 ± 8.1 vs. 25.8 ± 10.4%, p < 0.001). After adjusting for total energy intake, age, sex, and diabetes duration, increased carbohydrate intake offset by an isoenergetic decrease in fat was associated with higher eGDR (β = 0.103, 95% CI 0.044–0.163). In contrast, increased dietary fat at the expense of dietary protein intake was associated with lower eGDR (β = − 0.119, 95% CI − 0.199 to − 0.040). Replacing fat with 5% isoenergetic amount of carbohydrate resulted in decreased vascular biomarkers (p < 0.05). Conclusion: Higher fat, but not carbohydrate, intake is associated with increased IR and an adverse vascular profile in patients with T1D.
- 10 December 2022
- Published by Springer Nature in European Journal of Nutrition
- Vol. 62 (3) , 1231-1238
Open AccessDietary fat intake is associated with insulin resistance and an adverse vascular profile in patients with T1D: a pooled analysis
Background: Insulin resistance (IR) increases vascular risk in individuals with Type 1 Diabetes (T1D). We aimed to investigate the relationship between dietary intake and IR, as well as vascular biomarkers in T1D. Methods: Baseline data from three randomised controlled trials were pooled. Estimated glucose disposal rate (eGDR) was used as an IR marker. Employing multivariate nutrient density substitution models, we examined the association between macronutrient composition and IR/vascular biomarkers (tumour necrosis factor-α, fibrinogen, tissue factor activity, and plasminogen activator inhibitor-1). Results: Of the 107 patients, 50.5% were male with mean age of 29 ± 6 years. Those with lower eGDR were older with a longer diabetes duration, higher insulin requirements, and an adverse vascular profile (p < 0.05). Patients with higher degrees of IR had higher total energy intake (3192 ± 566 vs. 2772 ± 268 vs. 2626 ± 395 kcal/d for eGDR < 5.1 vs. 5.1–8.6 vs. ≥ 8.7 mg/kg/min, p < 0.001) and consumed a higher absolute and proportional amount of fat (47.6 ± 18.6 vs. 30.4 ± 8.1 vs. 25.8 ± 10.4%, p < 0.001). After adjusting for total energy intake, age, sex, and diabetes duration, increased carbohydrate intake offset by an isoenergetic decrease in fat was associated with higher eGDR (β = 0.103, 95% CI 0.044–0.163). In contrast, increased dietary fat at the expense of dietary protein intake was associated with lower eGDR (β = − 0.119, 95% CI − 0.199 to − 0.040). Replacing fat with 5% isoenergetic amount of carbohydrate resulted in decreased vascular biomarkers (p < 0.05). Conclusion: Higher fat, but not carbohydrate, intake is associated with increased IR and an adverse vascular profile in patients with T1D.
- Top Cited PapersOpen Access
- 1 December 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 55, 101762
The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis
- 1 December 2022
- Published by Elsevier in eClinicalMedicine
- Vol. 55, 101762
Top Cited PapersOpen AccessThe prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis
- Open Access
- 20 June 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (9) , 1850-1860
The impact of the COVID‐19 pandemic on glycaemic control in people with diabetes: A systematic review and meta‐analysis
Aim: To identify, appraise and synthesize the available evidence on the impact of the coronavirus disease 2019 (COVID‐19) pandemic and lockdown (LD) on glycaemic control in people with diabetes. Materials and Methods: We searched multiple databases up to 2 February 2021 for studies reporting HbA1c, time in range (TIR), average or fasting glucose, severe hypoglycaemia and diabetic ketoacidosis. Data were pooled using random effects meta‐analysis and are presented as mean difference (MD) with 95% confidence intervals (CI). This review was preregistered on PROSPERO (CRD42020179319). Results: We include 59 studies; 44 (n = 15 464) were included in quantitative syntheses and 15 were narratively synthesized. Pooled data were grouped by diabetes type. Results from 28 studies (n = 5048 type 1 diabetes [T1D] and combined diabetes participants) showed that TIR increased during LD compared with before LD (MD 2.74%, 95% CI 1.80% to 3.69%). Data from 10 studies (n = 1294 T1D participants) showed that TIR increased after LD compared with before LD (MD 5.14%, 95% CI 3.12% to 7.16%). Pooled results from 12 studies (n = 4810 T1D and type 2 diabetes participants) resulted in average glucose decreasing after LD compared with before LD (MD –6.86 mg/dl, 95% CI –8.54 to –5.18). Results for other outcomes, including HbA1c, were not statistically significantly different. Conclusions: The COVID‐19 pandemic was associated with small improvements across multiple outcomes of glycaemic control, although there was insufficient evidence to suggest that this led to changes in HbA1c. Most evidence came from people with access to diabetes technologies in high‐income countries; more research is needed in less advantaged populations.
- 20 June 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (9) , 1850-1860
Open AccessThe impact of the COVID‐19 pandemic on glycaemic control in people with diabetes: A systematic review and meta‐analysis
Aim: To identify, appraise and synthesize the available evidence on the impact of the coronavirus disease 2019 (COVID‐19) pandemic and lockdown (LD) on glycaemic control in people with diabetes. Materials and Methods: We searched multiple databases up to 2 February 2021 for studies reporting HbA1c, time in range (TIR), average or fasting glucose, severe hypoglycaemia and diabetic ketoacidosis. Data were pooled using random effects meta‐analysis and are presented as mean difference (MD) with 95% confidence intervals (CI). This review was preregistered on PROSPERO (CRD42020179319). Results: We include 59 studies; 44 (n = 15 464) were included in quantitative syntheses and 15 were narratively synthesized. Pooled data were grouped by diabetes type. Results from 28 studies (n = 5048 type 1 diabetes [T1D] and combined diabetes participants) showed that TIR increased during LD compared with before LD (MD 2.74%, 95% CI 1.80% to 3.69%). Data from 10 studies (n = 1294 T1D participants) showed that TIR increased after LD compared with before LD (MD 5.14%, 95% CI 3.12% to 7.16%). Pooled results from 12 studies (n = 4810 T1D and type 2 diabetes participants) resulted in average glucose decreasing after LD compared with before LD (MD –6.86 mg/dl, 95% CI –8.54 to –5.18). Results for other outcomes, including HbA1c, were not statistically significantly different. Conclusions: The COVID‐19 pandemic was associated with small improvements across multiple outcomes of glycaemic control, although there was insufficient evidence to suggest that this led to changes in HbA1c. Most evidence came from people with access to diabetes technologies in high‐income countries; more research is needed in less advantaged populations.
- Open Access
- 1 May 2022
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 19 (3)
Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study
Aims/Hypothesis: We hypothesised that the detrimental effect of high glucose variability (GV) in people with type 1 diabetes is mainly evident in those with concomitant insulin resistance. Methods: We conducted secondary analyses on continuous glucose monitoring (CGM) using baseline observational data from three randomised controlled trials and assessed the relationship with established vascular markers. We used standard CGM summary statistics and principal component analysis to generate individual glucose variability signatures for each participant. Cluster analysis was then employed to establish three GV clusters (low, intermediate, or high GV, respectively). The relationship with thrombotic biomarkers was then investigated according to insulin resistance, assessed as estimated glucose disposal rate (eGDR). Results: Of 107 patients, 45%, 37%, and 18% of patients were assigned into low, intermediate, and high GV clusters, respectively. Thrombosis biomarkers (including fibrinogen, plasminogen activator inhibitor-1, tissue factor activity, and tumour necrosis factor-alpha) increased in a stepwise fashion across all three GV clusters; this increase in thrombosis markers was evident in the presence of low but not high eGDR and at a threshold of eGDR <5.1 mg/kg/min. Conclusion: Higher GV is associated with increased thrombotic biomarkers in type 1 diabetes but only in those with concomitant insulin resistance.
- 1 May 2022
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 19 (3)
Open AccessGlucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study
Aims/Hypothesis: We hypothesised that the detrimental effect of high glucose variability (GV) in people with type 1 diabetes is mainly evident in those with concomitant insulin resistance. Methods: We conducted secondary analyses on continuous glucose monitoring (CGM) using baseline observational data from three randomised controlled trials and assessed the relationship with established vascular markers. We used standard CGM summary statistics and principal component analysis to generate individual glucose variability signatures for each participant. Cluster analysis was then employed to establish three GV clusters (low, intermediate, or high GV, respectively). The relationship with thrombotic biomarkers was then investigated according to insulin resistance, assessed as estimated glucose disposal rate (eGDR). Results: Of 107 patients, 45%, 37%, and 18% of patients were assigned into low, intermediate, and high GV clusters, respectively. Thrombosis biomarkers (including fibrinogen, plasminogen activator inhibitor-1, tissue factor activity, and tumour necrosis factor-alpha) increased in a stepwise fashion across all three GV clusters; this increase in thrombosis markers was evident in the presence of low but not high eGDR and at a threshold of eGDR <5.1 mg/kg/min. Conclusion: Higher GV is associated with increased thrombotic biomarkers in type 1 diabetes but only in those with concomitant insulin resistance.